1.
ACS Med Chem Lett
; 9(7): 652-656, 2018 Jul 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30034595
RESUMO
Identification of ligands that selectively activate the M1 muscarinic signaling pathway has been sought for decades to treat a range of neurological and cognitive disorders. Herein, we describe the optimization efforts focused on addressing key physicochemical and safety properties, ultimately leading to the clinical candidate MK-7622, a highly selective positive allosteric modulator of the M1 muscarinic receptor that has entered Phase II studies in patients with Alzheimer's disease.